What is Lifesci Capital’s Estimate for Liquidia Q2 Earnings?

Liquidia Co. (NASDAQ:LQDA) – Equities researchers at Lifesci Capital issued their Q2 2025 EPS estimates for Liquidia in a research report issued to clients and investors on Wednesday, March 19th. Lifesci Capital analyst C. Jubinville expects that the company will earn ($0.35) per share for the quarter. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. Lifesci Capital also issued estimates for Liquidia’s Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.41) EPS.

A number of other equities research analysts have also recently issued reports on the company. Wells Fargo & Company assumed coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective on the stock. Needham & Company LLC upped their price target on shares of Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Liquidia in a research note on Thursday, March 20th. Finally, Scotiabank boosted their price objective on shares of Liquidia from $30.00 to $34.00 and gave the stock a “sector outperform” rating in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $26.63.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $15.60 on Monday. The stock has a 50 day moving average price of $14.95 and a 200 day moving average price of $12.32. The stock has a market capitalization of $1.33 billion, a PE ratio of -9.57 and a beta of 0.07. Liquidia has a 52 week low of $8.26 and a 52 week high of $16.81.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%.

Insider Buying and Selling at Liquidia

In other news, insider Rajeev Saggar sold 6,249 shares of the business’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $73,613.22. Following the completion of the sale, the insider now owns 270,388 shares in the company, valued at $3,185,170.64. The trade was a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Russell Schundler sold 16,393 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the transaction, the general counsel now directly owns 573,478 shares in the company, valued at $6,755,570.84. The trade was a 2.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,245 shares of company stock worth $843,326 over the last ninety days. Insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in Liquidia by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company’s stock worth $41,834,000 after acquiring an additional 115,367 shares during the period. LM Advisors LLC acquired a new position in shares of Liquidia during the 4th quarter worth approximately $25,948,000. Whitefort Capital Management LP raised its position in shares of Liquidia by 16.8% in the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock valued at $23,370,000 after buying an additional 285,220 shares in the last quarter. Vestal Point Capital LP raised its position in shares of Liquidia by 17.3% in the fourth quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company’s stock valued at $20,698,000 after buying an additional 260,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Liquidia by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company’s stock valued at $15,753,000 after buying an additional 101,597 shares during the period. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).